PT - JOURNAL ARTICLE AU - Jin, Xin AU - Wang, Yanqun AU - Xu, Jinjin AU - Li, Yimin AU - Cheng, Fanjun AU - Luo, Yuxue AU - Zhou, Haibo AU - Lin, Shanwen AU - Xiao, Fei AU - Zhang, Lu AU - Lin, Yu AU - Zhang, Zhaoyong AU - Jin, Yan AU - Zheng, Fang AU - Chen, Wei AU - Zhu, Airu AU - Tao, Ye AU - Zhao, Jingxian AU - Kuo, Tingyou AU - Li, Yuming AU - Li, Lingguo AU - Wen, Liyan AU - Ou, Rijing AU - Li, Fang AU - Lin, Long AU - Zhang, Yanjun AU - Sun, Jing AU - Yuan, Hao AU - Zhuang, Zhen AU - Sun, Haixi AU - Chen, Zhao AU - Li, Jie AU - Zhuo, Jianfen AU - Chen, Dongsheng AU - Zhang, Shengnan AU - Sun, Yuzhe AU - Wei, Peilan AU - Yuan, Jinwei AU - Xu, Tian AU - Yang, Huanming AU - Wang, Jian AU - Xu, Xun AU - Zhong, Nanshan AU - Xu, Yonghao AU - Sun, Kun AU - Zhao, Jincun TI - Plasma cell-free DNA promise disease monitoring and tissue injury assessment of COVID-19 AID - 10.1101/2021.07.19.21260139 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.19.21260139 4099 - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260139.short 4100 - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260139.full AB - COVID-19 is a huge threat to global health. Due to the lack of definitive etiological therapeutics currently, effective disease monitoring is of high clinical value for better healthcare and management of the large number of COVID-19 patients. In this study, we recruited 37 COVID-19 patients, collected 176 blood samples upon diagnosis and during treatment, and analyzed cell-free DNA (cfDNA) in these samples. We report gross abnormalities in cfDNA of COVID-19 patients, including elevated GC content, altered molecule size and end motif patterns. More importantly, such cfDNA characteristics reflect patient-specific physiological conditions during treatment. Further analysis on tissue origin tracing of cfDNA reveals frequent tissue injuries in COVID-19 patients, which is supported by clinical diagnoses. Hence, we demonstrate the translational merit of cfDNA as valuable analyte for effective disease monitoring, as well as tissue injury assessment in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to thank Ms. Qi Wang from Shenzhen Bay Laboratory for her technical assistance. This study has been supported by China National GeneBank (CNGB), Shenzhen Bay Laboratory, National Key Research and Development Program of China (2018YFC1200100 to JZ), National Science and Technology Major Project (2018ZX10301403 to JZ), the emergency grants for prevention and control of SARS-CoV-2 of Ministries of Science and Technology, and Education of Guangdong province (2020A111128008, 2020B1111320003, 2020KZDZX1158 to JZ, and 2020B1111330001 to NZ), National Natural Science Foundation of China (32000398 to XJ), Natural Science Foundation of Guangdong Province, China (2017A030306026 to XJ), Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases (2019B121205005 to XJ), Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011 to XX), Guangdong Provincial Academician Workstation of BGI Synthetic Genomics (No. 2017B090904014 to HY), and BGI-research (BGIRSZ2020007 to KS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study had been approved by The First Affiliate Hospital of Guangzhou Medical University Ethics Committee, and the institutional review board of BGI; written informed consents had been obtained from all patients and healthy donor participated in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData access The data that support the findings of this study have been deposited into CNGB Sequence Archive (CNSA)(70) of China National GeneBank DataBase (CNGBdb) (71) with accession number CNP0001306. https://db.cngb.org/cnsa/project/CNP0001306/reviewlink/